Regulation, reimbursement and HTA hold up EU access to cancer drugs, says report
This article was originally published in SRA
Executive Summary
Access to cancer drugs by patients in the European Union can be significantly restricted by regulatory obstacles, pricing and reimbursement hurdles and health technology assessment procedures, a new industry-sponsored report has indicated1.
You may also be interested in...
Pharma Guidelines, ending 1 July 2011
Recently updated and newly issued documents
EuropaBio appoints new chairman
EuropaBio, the European biotech industry association, has appointed Stephan Tanda as its new association chair. Mr Tanda, a member of the managing board of life sciences and materials sciences firm DSM, succeeds GlaxoSmithKline's Andrea Rappagliosi, who will remain a member of the EuropaBio board.
Medtech Guidelines, ending 24 June 2011
Recently updated and newly issued documents